arrow
F

Fabrizio Citarella

istituto nazionale tumori fondazione g pascale
H指数:23
被引数:1,682

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Venous thromboembolism reporting in fusion-positive NSCLC treated with tyrosine kinase inhibitors: A systematic review of safety reporting and protocol-level provisions in phase I-IV clinical trials

酪氨酸激酶抑制剂治疗融合阳性非小细胞肺癌中的静脉血栓栓塞事件报告:一项关于安全性报告和方案级规定在I-IV期临床试验的系统综述

2026-10-270
OAAI
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study

根据KRAS状态评估一线化疗联合免疫疗法在晚期非鳞状NSCLC中的疗效:一项意大利真实世界研究

2026-08-010
PRE
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis

局部消融疗法(LAT)与表皮生长因子受体酪氨酸激酶抑制剂(TKIs)在晚期EGFR阳性非小细胞肺癌(NSCLC)中的首线整合:一项系统评价和荟萃分析

2026-04-210
OAAI
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional − prospective study to inform referral for germline testing

非小细胞肺癌中的家族史信息补充:一项用于指导胚系检测转诊的横断面-前瞻性研究

2026-02-260
OAAI
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database

Braf突变转移性非小细胞肺癌: 来自意大利生物标志物图谱数据库的真实世界数据

2026-01-210
OAAI
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较(FRONT-BRAF):一项多中心、回顾性队列研究

2025-09-290
PRE
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2025-09-240
OAAI
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

肺大细胞神经内分泌癌的整合分子与临床特征分析

2025-08-190
OA
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients

吸烟者和从未吸烟者肺鳞癌患者的基因组与转录组特征

2025-06-280
OA
Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2024-09-010
PRE
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database

非小细胞肺癌中的MET外显子14跳跃突变: 来自意大利生物标志物图谱数据库的真实数据

2024-09-010
OAAI
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)
2024-07-312
OAAI
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024-05-013
PRE
Clinical features of progression and outcomes with subsequent therapies in patients treated with RET-inhibitors
2023-12-010
PRE